Roles of MiR-101 and its Target Gene Cox-2 in Early Diagnosis of Cervical Cancer in Uygur Women |
Lin, Chen
(Department of Pathology, College of Basic Medicine, Xinjiang Medical University)
Huang, Fei (Department of Pathology, College of Basic Medicine, Xinjiang Medical University) Zhang, Ya-Jing (Department of Pathology, The Forth Affiliated Hospital, Xinjiang Medical University) Tuokan, Talafu (Department of Pathology, College of Basic Medicine, Xinjiang Medical University) Kuerban, Gulinaer (Department of Pathology, College of Basic Medicine, Xinjiang Medical University) |
1 | Hao Y, Gu X, Zhao Y (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the Cox-2 pathway in vivo. Cancer Prev Res, 4, 1073-83. DOI ScienceOn |
2 | Wang HJ, Ruan HJ, He XJ, et al (2010). MicroRNA-101 is downregulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer, 46, 2295-303. DOI ScienceOn |
3 | Wang R, Wang HB, Hao CJ, et al (2012). MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One, 7, e46173. DOI |
4 | Wu ZL, Zheng SS, Li ZM, et al (2010). Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ, 17, 801-10. DOI ScienceOn |
5 | Zhang Y, Guo X, Xiong L, et al (2012). MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett, 586, 4362-70. DOI ScienceOn |
6 | Hao Y, Gu X, Zhao Y, et al (2011). Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the Cox-2 pathway in vivo. Cancer Prev Res, 4, 1073-83. DOI ScienceOn |
7 | Cao W, Ribeiro Rde O, Liu D, et al (2012). EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with nonsmall cell lung cancer. PLoS One, 7, e52984. DOI |
8 | Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, et al (2012). MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther, 13, 175-83. DOI |
9 | Chen J, Yao D, Li Y (2013). Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervicalsquamous cell carcinoma. Int J Mol Med, 32, 557-67. |
10 | Garzon R, Calin GA, Croce CM (2009). MicroRNAs in Cancer. Annu Rev Med, 60, 167-79. DOI ScienceOn |
11 | Lalaisuzuke, Peng YH, Zhou K, et al (2006). The analysis of pathogenetic tendency of cervical cancer in various ethnic women in Xinjiang. J Xinjiang Med Univ, 29, 569-71. |
12 | Lee JW, Choi CH, Choi JJ (2008). Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res, 14, 2535-42. DOI ScienceOn |
13 | Pang Y, Young CY, Yuan H (2010). MicroRNAs and prostate cancer. Acta Biochem Biophys Sin, 42, 363-9. DOI ScienceOn |
14 | Rao Q, Shen Q, Zhou H, et al. Aberrant microRNA expression in human cervical carcinomas. Med Oncol, 29, 1242-8. |
15 | Strillacci A, Valerii MC, Sansone P (2013) Loss of miR-101 expression promotes Wnt/-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol, 229, 379-89. DOI ScienceOn |
16 | Bumgarner SL, Dowell RD, Grisafi P, et al (2009). Toggle involving cis-interfering noncoding RNAs controls variegated gene expreassion in yeast. Proc Natl Acad Sci USA, 106, 18321-6. DOI ScienceOn |
17 | Su H, Yang JR, Xu T, et al (2009). MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69, 1135-42. |
18 | Arbyn M, Castellsague X, de Sanjose S, et al (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol, 22, 2675-86. DOI ScienceOn |
19 | Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33. DOI ScienceOn |
20 | Zhang JG, Guo JF, Liu DL, et al (2011). MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol, 6, 671-8. DOI ScienceOn |